Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Website: pfizer.com


  • Good financial results growth rate 98.6% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (2.1%)
  • Dividend yield for the last twelve months 6.9%
  • Free cash flow yield 9.9% (LTM)
  • Share price is 14.7% higher than minimum and 54.5% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (10.8x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: PFE
Share price, USD:  (0.0%)24.77
year average price 25.02  


year start price 28.92 2024-10-29

max close price 28.92 2024-10-29

min close price 21.59 2025-04-10

current price 24.77 2025-10-28
Common stocks: 5 615 000 000

Dividend Yield:  6.9%
FCF Yield LTM: 9.9%
EV / LTM EBITDA: 10.8x
EV / EBITDA annualized: 10.1x
Last revenue growth (y/y):  +10.3%
Last growth of EBITDA (y/y):  +186.8%
Historical revenue growth:  -10.3%
Historical growth of EBITDA:  +14.6%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 139 084
Net Debt ($m): 48 865
EV (Enterprise Value): 187 949
EBITDA LTM ($m): 17 323
EV / LTM EBITDA: 10.8x
Price to Book: 1.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-10-24seekingalpha.com

Why Pfizer's Headwinds May Already Be In The Price

2025-10-20zacks.com

Pfizer's Q3 Non-Oncology Performance: Here's What to Expect

2025-10-19businesswire.com

XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer

2025-10-19businesswire.com

Pfizer's BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer

2025-10-18reuters.com

Astellas-Pfizer's combination therapy halves risk of death in bladder cancer patients

2025-10-18prnewswire.com

PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer

2025-10-18seekingalpha.com

Pfizer: World-Leading Drug Pipeline Sets Stage For Major Long-Term Potential

2025-10-17zacks.com

Pfizer (PFE) Beats Stock Market Upswing: What Investors Need to Know

2025-10-17forbes.com

What's Behind The Slump In Pfizer Stock?

2025-10-16seekingalpha.com

Pfizer: Don't Forget About Value During AI Frenzy
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data